BioAtla Investor Conference Presentation Deck
Significant opportunity for BA3011 in Sarcoma and NSCLC
to fill unmet medical needs
++
bicatla
Current treatments for AXL+ tumors are insufficient, leading to high recurrence rates,
rapid progression, low survival rates, and drug-related toxicities
Our Phase 1 studies revealed positive clinical signals across sarcoma and NSCLC,
demonstrated by durable clinical responses (PFS and PR), and reductions in tumor size
We have two ongoing Phase 2 studies in sarcoma and NSCLC
We are excited to advance towards our transition to commercial-stage company while
filling a significant unmet medical need for patients with AXL+ solid tumors
NSCLC, non-small cell lung cancer; PFS, progression-free survival; PR, partial response.
BioAtla Overview | Company Confidential 7View entire presentation